SI
ACAD icon

Sofinnova Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Sofinnova Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$8.3M – 64
2025
Q1 		$8.3M Buy
+500,000
New +$9.08M 0.54% 42
2021
Q3 		– Sell
-100,000
Closed -$2.44M – 71
2021
Q2 		$2.44M Buy
+100,000
New +$2.26M 0.14% 61

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Sofinnova Investments's ACAD Position: Q1 2026 in Review

Sofinnova Investments increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q1 2026, buying an estimated $310K and bringing the position to 78,551 shares worth $1.75M. The position accounts for 0.07% of the portfolio, ranked #65.

Sofinnova Investments first reported a position in ACAD in Q2 2019 and has held it in 6 quarters since. The position peaked at $8.8M in Q4 2020. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Sofinnova Investments held 78,551 shares of Acadia Pharmaceuticals worth $1.75M as of Q1 2026.
  • Sofinnova Investments bought 12,984 Acadia Pharmaceuticals shares in Q1 2026, an estimated $310K.
  • Acadia Pharmaceuticals made up 0.07% of Sofinnova Investments's portfolio in Q1 2026, its #65 holding.
  • Sofinnova Investments first reported a position in Acadia Pharmaceuticals in Q2 2019 and has held it in 6 quarters since.
  • Sofinnova Investments's Acadia Pharmaceuticals position peaked at $8.8M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.